AILY LABS BCG MATRIX TEMPLATE RESEARCH
Download Your Competitive Advantage
Aily Labs' BCG Matrix preview shows early signals of which products may be Stars or Question Marks amid rapid market shifts-valuable, but incomplete. Purchase the full BCG Matrix for a quadrant-by-quadrant breakdown, precise market-share and growth metrics, and actionable recommendations to reallocate capital or double down on winners.
Stars
AI-Native Decision Intelligence App
Aily Labs' AI-Native Decision Intelligence App is a Star: mobile-first, dominant in the Fortune 500, and at $28.6 million ARR by mid-2025, driven by 500% YoY customer growth.
It powers real-time executive decisions and, given the decision intelligence market's projected $28.5 billion size by 2028, justifies continued high investment as a high-reward leader.
Pharmaceutical Vertical (.r&d)
Aily Labs' Pharmaceutical R&D unit (plai) holds a near-monopoly in AI-driven R&D orchestration with major partners like Sanofi, capturing an estimated 65% market share in enterprise pharma AI by FY2025 and driving $120M ARR across pharma contracts.
The plai module optimizes clinical-trial data and resource allocation, cutting trial cycle costs by ~22% and delivering measurable ROI in under two weeks per pilot, per Sanofi deployment (2025).
High regulatory barriers, IP moat, and integration depth keep churn under 5% annually, supporting rapid sector growth projected at 28% CAGR for AI in pharma R&D through 2028.
Super Agent Ecosystem
Aily Labs' Super Agent Ecosystem, launched as a breakthrough in agentic AI, orchestrates autonomous agents that recommend and execute high‑stakes business decisions and drove 2025 pilot ARR of $18.4M across 27 enterprise clients.
The product is the focal point of Aily Labs' $80M Series B (closed Q4 2025) to fund R&D and go‑to‑market, preserving a 9-12 month first‑to‑market lead.
As the cutting edge of AI autonomy, it targets a $62B autonomous enterprise TAM by 2028 and attracted $46M of the round from strategic AI investors.
Supply Chain Module (.supply)
Supply Chain Module (.supply) is a Star: it delivered end-to-end visibility and inventory optimization to global consumer goods and retail giants, driving 48% YoY revenue growth in 2025 and securing a 32% share of Aily Labs' ARR of $210M.
By unifying fragmented data silos it produced 100% of lead clients' 2025 forecasts and drafted 2026 budgets in under 30 days versus industry average 90+ days; strong 2025 demand for resilience keeps it high-growth, high-share.
- 48% YoY revenue growth 2025
- 32% share of Aily Labs ARR ($67.2M)
- 100% lead-client forecasts for 2025
- 2026 budgets in <30 days vs 90+ industry days
- High demand for supply chain resilience in 2025
Finance and Resource Allocation (.fin)
The .fin module has captured ~18% share of Fortune 500 CFO deployments in 2025, automating dynamic budgeting and capital allocation and cutting forecast cycle time by 42% versus legacy BI tools.
Proprietary LLMs translate raw ERP and treasury data into P&L impact in under 2 hours on average; J.P. Morgan's 2025 strategic investment increases channel access to 1,200 institutional seats globally.
- 18% Fortune 500 CFO adoption (2025)
- 42% faster forecast cycles vs legacy BI
- Median P&L impact reporting <2 hours
- 1,200 institutional seats via J.P. Morgan partnership
AI-Native Winners: Rapid ARR, Pharma Dominance, and Enterprise Finance Gains
Aily Labs Stars: AI-Native App-$28.6M ARR (mid‑2025), 500% YoY growth; plai-$120M ARR, ~65% pharma AI share, 22% trial cost cut; Super Agent-$18.4M pilot ARR, $80M Series B; .supply-$67.2M (32% ARR), 48% YoY; .fin-18% Fortune 500 CFOs, 42% faster forecasts.
| Product | 2025 $ | Share/Metric |
|---|---|---|
| AI App | $28.6M | 500% YoY |
| plai | $120M | 65% pharma AI |
| Super Agent | $18.4M | Series B $80M |
| .supply | $67.2M | 32% ARR, 48% YoY |
| .fin | - | 18% CFOs, 42% faster |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix of Aily Labs: strategic guidance on Stars, Cash Cows, Question Marks, and Dogs with invest/hold/divest calls and trend context.
Customizable Excel Spreadsheet
One-page overview placing each business unit in a quadrant for quick strategic decisions
Cash Cows
Core Enterprise Data Integration Layer
The Core Enterprise Data Integration Layer is a mature, high-market-share cash cow in Aily Labs' 2025 stack, delivering steady revenue with ~$85M ARR and ~60% gross margin while requiring under 8% of total R&D spend versus agentic layers.
It serves as the mandatory single-source-of-truth for Fortune 500 deployments-accounting for 72% of new enterprise deals in FY2025-and funds growth of higher-risk modules.
Healthcare Operational Analytics
Healthcare Operational Analytics, Aily Labs' 2020 core, now shows market maturity with 92% client retention in FY2025 and an annual recurring revenue of $48.3M, delivering 38% gross margins and low sales churn.
These stable cash flows require minimal promotion due to strong brand recognition; surplus cash of $16.4M in FY2025 is earmarked to fund next-gen autonomous agents R&D.
Mobile-First Executive Dashboards
Mobile-First Executive Dashboards at Aily Labs hold a 62% market share among C-suite users in 2025, driving $18.4M ARR and showing 88% retention; the UI is mature and needs only incremental patches to stay best-in-class.
Legacy Decision Support Systems
Legacy Decision Support Systems continue to serve ~420 enterprise clients, generating $38.5M in 2025 recurring subscription revenue (≈48% gross margin), and account for ~35% of Aily Labs' ARR, funding R&D for the Star autonomous products.
Market growth for non-autonomous AI slowed to 4% CAGR (2023-25), yet these systems retain ~22% market share in regulated industries and deliver predictable cash flow used to subsidize higher-growth bets.
- 420 enterprise clients
- $38.5M 2025 subscription revenue
- 35% of Aily Labs ARR
- 4% CAGR market growth (2023-25)
- 22% share in regulated sectors
Professional Services and Integration Consulting
Aily Labs' Professional Services and Integration Consulting is a high-margin cash cow: one-day integrations for enterprise clients yield implementation market share ~28% in 2025 and annual service revenue of $62.4M, stabilizing growth as the platform becomes plug-and-play.
Services cover ~14% of 2025 operating expenses and fund debt interest of $9.2M, requiring little incremental capital while sustaining margins near 48%.
- One-day integrations: 28% market share
- 2025 service revenue: $62.4M
- Margin: ~48%
- Covers 14% of opex; funds $9.2M interest
$252M ARR portfolio fuels $16.4M FY25 surplus to fund autonomous R&D
The Core Enterprise Data Integration Layer ($85M ARR, 60% GM), Healthcare Operational Analytics ($48.3M ARR, 38% GM), Mobile-First Dashboards ($18.4M ARR, 88% retention), Legacy DSS ($38.5M ARR, 48% GM) and Services ($62.4M, 48% GM) deliver stable cash flows; FY2025 surplus $16.4M funds autonomous R&D.
| Product | 2025 ARR | GM | Notes |
|---|---|---|---|
| Data Integration | $85M | 60% | 72% new deals |
| Healthcare Analytics | $48.3M | 38% | 92% retention |
| Dashboards | $18.4M | - | 62% C-suite share |
| Legacy DSS | $38.5M | 48% | 420 clients |
| Services | $62.4M | 48% | covers 14% opex |
What You're Viewing Is Included
Aily Labs BCG Matrix
The file you're previewing is the exact Aily Labs BCG Matrix report you'll receive after purchase-no watermarks, placeholders, or demo content. Fully formatted and analysis-ready, the document arrives immediately for editing, printing, or presenting to stakeholders. Crafted with market-backed insights and strategic clarity, it requires no revisions and can be integrated straight into your planning, pitch decks, or client deliverables.
AILY LABS BCG MATRIX TEMPLATE RESEARCH
Download Your Competitive Advantage
Aily Labs' BCG Matrix preview shows early signals of which products may be Stars or Question Marks amid rapid market shifts-valuable, but incomplete. Purchase the full BCG Matrix for a quadrant-by-quadrant breakdown, precise market-share and growth metrics, and actionable recommendations to reallocate capital or double down on winners.
Stars
AI-Native Decision Intelligence App
Aily Labs' AI-Native Decision Intelligence App is a Star: mobile-first, dominant in the Fortune 500, and at $28.6 million ARR by mid-2025, driven by 500% YoY customer growth.
It powers real-time executive decisions and, given the decision intelligence market's projected $28.5 billion size by 2028, justifies continued high investment as a high-reward leader.
Pharmaceutical Vertical (.r&d)
Aily Labs' Pharmaceutical R&D unit (plai) holds a near-monopoly in AI-driven R&D orchestration with major partners like Sanofi, capturing an estimated 65% market share in enterprise pharma AI by FY2025 and driving $120M ARR across pharma contracts.
The plai module optimizes clinical-trial data and resource allocation, cutting trial cycle costs by ~22% and delivering measurable ROI in under two weeks per pilot, per Sanofi deployment (2025).
High regulatory barriers, IP moat, and integration depth keep churn under 5% annually, supporting rapid sector growth projected at 28% CAGR for AI in pharma R&D through 2028.
Super Agent Ecosystem
Aily Labs' Super Agent Ecosystem, launched as a breakthrough in agentic AI, orchestrates autonomous agents that recommend and execute high‑stakes business decisions and drove 2025 pilot ARR of $18.4M across 27 enterprise clients.
The product is the focal point of Aily Labs' $80M Series B (closed Q4 2025) to fund R&D and go‑to‑market, preserving a 9-12 month first‑to‑market lead.
As the cutting edge of AI autonomy, it targets a $62B autonomous enterprise TAM by 2028 and attracted $46M of the round from strategic AI investors.
Supply Chain Module (.supply)
Supply Chain Module (.supply) is a Star: it delivered end-to-end visibility and inventory optimization to global consumer goods and retail giants, driving 48% YoY revenue growth in 2025 and securing a 32% share of Aily Labs' ARR of $210M.
By unifying fragmented data silos it produced 100% of lead clients' 2025 forecasts and drafted 2026 budgets in under 30 days versus industry average 90+ days; strong 2025 demand for resilience keeps it high-growth, high-share.
- 48% YoY revenue growth 2025
- 32% share of Aily Labs ARR ($67.2M)
- 100% lead-client forecasts for 2025
- 2026 budgets in <30 days vs 90+ industry days
- High demand for supply chain resilience in 2025
Finance and Resource Allocation (.fin)
The .fin module has captured ~18% share of Fortune 500 CFO deployments in 2025, automating dynamic budgeting and capital allocation and cutting forecast cycle time by 42% versus legacy BI tools.
Proprietary LLMs translate raw ERP and treasury data into P&L impact in under 2 hours on average; J.P. Morgan's 2025 strategic investment increases channel access to 1,200 institutional seats globally.
- 18% Fortune 500 CFO adoption (2025)
- 42% faster forecast cycles vs legacy BI
- Median P&L impact reporting <2 hours
- 1,200 institutional seats via J.P. Morgan partnership
AI-Native Winners: Rapid ARR, Pharma Dominance, and Enterprise Finance Gains
Aily Labs Stars: AI-Native App-$28.6M ARR (mid‑2025), 500% YoY growth; plai-$120M ARR, ~65% pharma AI share, 22% trial cost cut; Super Agent-$18.4M pilot ARR, $80M Series B; .supply-$67.2M (32% ARR), 48% YoY; .fin-18% Fortune 500 CFOs, 42% faster forecasts.
| Product | 2025 $ | Share/Metric |
|---|---|---|
| AI App | $28.6M | 500% YoY |
| plai | $120M | 65% pharma AI |
| Super Agent | $18.4M | Series B $80M |
| .supply | $67.2M | 32% ARR, 48% YoY |
| .fin | - | 18% CFOs, 42% faster |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix of Aily Labs: strategic guidance on Stars, Cash Cows, Question Marks, and Dogs with invest/hold/divest calls and trend context.
Customizable Excel Spreadsheet
One-page overview placing each business unit in a quadrant for quick strategic decisions
Cash Cows
Core Enterprise Data Integration Layer
The Core Enterprise Data Integration Layer is a mature, high-market-share cash cow in Aily Labs' 2025 stack, delivering steady revenue with ~$85M ARR and ~60% gross margin while requiring under 8% of total R&D spend versus agentic layers.
It serves as the mandatory single-source-of-truth for Fortune 500 deployments-accounting for 72% of new enterprise deals in FY2025-and funds growth of higher-risk modules.
Healthcare Operational Analytics
Healthcare Operational Analytics, Aily Labs' 2020 core, now shows market maturity with 92% client retention in FY2025 and an annual recurring revenue of $48.3M, delivering 38% gross margins and low sales churn.
These stable cash flows require minimal promotion due to strong brand recognition; surplus cash of $16.4M in FY2025 is earmarked to fund next-gen autonomous agents R&D.
Mobile-First Executive Dashboards
Mobile-First Executive Dashboards at Aily Labs hold a 62% market share among C-suite users in 2025, driving $18.4M ARR and showing 88% retention; the UI is mature and needs only incremental patches to stay best-in-class.
Legacy Decision Support Systems
Legacy Decision Support Systems continue to serve ~420 enterprise clients, generating $38.5M in 2025 recurring subscription revenue (≈48% gross margin), and account for ~35% of Aily Labs' ARR, funding R&D for the Star autonomous products.
Market growth for non-autonomous AI slowed to 4% CAGR (2023-25), yet these systems retain ~22% market share in regulated industries and deliver predictable cash flow used to subsidize higher-growth bets.
- 420 enterprise clients
- $38.5M 2025 subscription revenue
- 35% of Aily Labs ARR
- 4% CAGR market growth (2023-25)
- 22% share in regulated sectors
Professional Services and Integration Consulting
Aily Labs' Professional Services and Integration Consulting is a high-margin cash cow: one-day integrations for enterprise clients yield implementation market share ~28% in 2025 and annual service revenue of $62.4M, stabilizing growth as the platform becomes plug-and-play.
Services cover ~14% of 2025 operating expenses and fund debt interest of $9.2M, requiring little incremental capital while sustaining margins near 48%.
- One-day integrations: 28% market share
- 2025 service revenue: $62.4M
- Margin: ~48%
- Covers 14% of opex; funds $9.2M interest
$252M ARR portfolio fuels $16.4M FY25 surplus to fund autonomous R&D
The Core Enterprise Data Integration Layer ($85M ARR, 60% GM), Healthcare Operational Analytics ($48.3M ARR, 38% GM), Mobile-First Dashboards ($18.4M ARR, 88% retention), Legacy DSS ($38.5M ARR, 48% GM) and Services ($62.4M, 48% GM) deliver stable cash flows; FY2025 surplus $16.4M funds autonomous R&D.
| Product | 2025 ARR | GM | Notes |
|---|---|---|---|
| Data Integration | $85M | 60% | 72% new deals |
| Healthcare Analytics | $48.3M | 38% | 92% retention |
| Dashboards | $18.4M | - | 62% C-suite share |
| Legacy DSS | $38.5M | 48% | 420 clients |
| Services | $62.4M | 48% | covers 14% opex |
What You're Viewing Is Included
Aily Labs BCG Matrix
The file you're previewing is the exact Aily Labs BCG Matrix report you'll receive after purchase-no watermarks, placeholders, or demo content. Fully formatted and analysis-ready, the document arrives immediately for editing, printing, or presenting to stakeholders. Crafted with market-backed insights and strategic clarity, it requires no revisions and can be integrated straight into your planning, pitch decks, or client deliverables.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Download Your Competitive Advantage
Aily Labs' BCG Matrix preview shows early signals of which products may be Stars or Question Marks amid rapid market shifts-valuable, but incomplete. Purchase the full BCG Matrix for a quadrant-by-quadrant breakdown, precise market-share and growth metrics, and actionable recommendations to reallocate capital or double down on winners.
Stars
AI-Native Decision Intelligence App
Aily Labs' AI-Native Decision Intelligence App is a Star: mobile-first, dominant in the Fortune 500, and at $28.6 million ARR by mid-2025, driven by 500% YoY customer growth.
It powers real-time executive decisions and, given the decision intelligence market's projected $28.5 billion size by 2028, justifies continued high investment as a high-reward leader.
Pharmaceutical Vertical (.r&d)
Aily Labs' Pharmaceutical R&D unit (plai) holds a near-monopoly in AI-driven R&D orchestration with major partners like Sanofi, capturing an estimated 65% market share in enterprise pharma AI by FY2025 and driving $120M ARR across pharma contracts.
The plai module optimizes clinical-trial data and resource allocation, cutting trial cycle costs by ~22% and delivering measurable ROI in under two weeks per pilot, per Sanofi deployment (2025).
High regulatory barriers, IP moat, and integration depth keep churn under 5% annually, supporting rapid sector growth projected at 28% CAGR for AI in pharma R&D through 2028.
Super Agent Ecosystem
Aily Labs' Super Agent Ecosystem, launched as a breakthrough in agentic AI, orchestrates autonomous agents that recommend and execute high‑stakes business decisions and drove 2025 pilot ARR of $18.4M across 27 enterprise clients.
The product is the focal point of Aily Labs' $80M Series B (closed Q4 2025) to fund R&D and go‑to‑market, preserving a 9-12 month first‑to‑market lead.
As the cutting edge of AI autonomy, it targets a $62B autonomous enterprise TAM by 2028 and attracted $46M of the round from strategic AI investors.
Supply Chain Module (.supply)
Supply Chain Module (.supply) is a Star: it delivered end-to-end visibility and inventory optimization to global consumer goods and retail giants, driving 48% YoY revenue growth in 2025 and securing a 32% share of Aily Labs' ARR of $210M.
By unifying fragmented data silos it produced 100% of lead clients' 2025 forecasts and drafted 2026 budgets in under 30 days versus industry average 90+ days; strong 2025 demand for resilience keeps it high-growth, high-share.
- 48% YoY revenue growth 2025
- 32% share of Aily Labs ARR ($67.2M)
- 100% lead-client forecasts for 2025
- 2026 budgets in <30 days vs 90+ industry days
- High demand for supply chain resilience in 2025
Finance and Resource Allocation (.fin)
The .fin module has captured ~18% share of Fortune 500 CFO deployments in 2025, automating dynamic budgeting and capital allocation and cutting forecast cycle time by 42% versus legacy BI tools.
Proprietary LLMs translate raw ERP and treasury data into P&L impact in under 2 hours on average; J.P. Morgan's 2025 strategic investment increases channel access to 1,200 institutional seats globally.
- 18% Fortune 500 CFO adoption (2025)
- 42% faster forecast cycles vs legacy BI
- Median P&L impact reporting <2 hours
- 1,200 institutional seats via J.P. Morgan partnership
AI-Native Winners: Rapid ARR, Pharma Dominance, and Enterprise Finance Gains
Aily Labs Stars: AI-Native App-$28.6M ARR (mid‑2025), 500% YoY growth; plai-$120M ARR, ~65% pharma AI share, 22% trial cost cut; Super Agent-$18.4M pilot ARR, $80M Series B; .supply-$67.2M (32% ARR), 48% YoY; .fin-18% Fortune 500 CFOs, 42% faster forecasts.
| Product | 2025 $ | Share/Metric |
|---|---|---|
| AI App | $28.6M | 500% YoY |
| plai | $120M | 65% pharma AI |
| Super Agent | $18.4M | Series B $80M |
| .supply | $67.2M | 32% ARR, 48% YoY |
| .fin | - | 18% CFOs, 42% faster |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix of Aily Labs: strategic guidance on Stars, Cash Cows, Question Marks, and Dogs with invest/hold/divest calls and trend context.
Customizable Excel Spreadsheet
One-page overview placing each business unit in a quadrant for quick strategic decisions
Cash Cows
Core Enterprise Data Integration Layer
The Core Enterprise Data Integration Layer is a mature, high-market-share cash cow in Aily Labs' 2025 stack, delivering steady revenue with ~$85M ARR and ~60% gross margin while requiring under 8% of total R&D spend versus agentic layers.
It serves as the mandatory single-source-of-truth for Fortune 500 deployments-accounting for 72% of new enterprise deals in FY2025-and funds growth of higher-risk modules.
Healthcare Operational Analytics
Healthcare Operational Analytics, Aily Labs' 2020 core, now shows market maturity with 92% client retention in FY2025 and an annual recurring revenue of $48.3M, delivering 38% gross margins and low sales churn.
These stable cash flows require minimal promotion due to strong brand recognition; surplus cash of $16.4M in FY2025 is earmarked to fund next-gen autonomous agents R&D.
Mobile-First Executive Dashboards
Mobile-First Executive Dashboards at Aily Labs hold a 62% market share among C-suite users in 2025, driving $18.4M ARR and showing 88% retention; the UI is mature and needs only incremental patches to stay best-in-class.
Legacy Decision Support Systems
Legacy Decision Support Systems continue to serve ~420 enterprise clients, generating $38.5M in 2025 recurring subscription revenue (≈48% gross margin), and account for ~35% of Aily Labs' ARR, funding R&D for the Star autonomous products.
Market growth for non-autonomous AI slowed to 4% CAGR (2023-25), yet these systems retain ~22% market share in regulated industries and deliver predictable cash flow used to subsidize higher-growth bets.
- 420 enterprise clients
- $38.5M 2025 subscription revenue
- 35% of Aily Labs ARR
- 4% CAGR market growth (2023-25)
- 22% share in regulated sectors
Professional Services and Integration Consulting
Aily Labs' Professional Services and Integration Consulting is a high-margin cash cow: one-day integrations for enterprise clients yield implementation market share ~28% in 2025 and annual service revenue of $62.4M, stabilizing growth as the platform becomes plug-and-play.
Services cover ~14% of 2025 operating expenses and fund debt interest of $9.2M, requiring little incremental capital while sustaining margins near 48%.
- One-day integrations: 28% market share
- 2025 service revenue: $62.4M
- Margin: ~48%
- Covers 14% of opex; funds $9.2M interest
$252M ARR portfolio fuels $16.4M FY25 surplus to fund autonomous R&D
The Core Enterprise Data Integration Layer ($85M ARR, 60% GM), Healthcare Operational Analytics ($48.3M ARR, 38% GM), Mobile-First Dashboards ($18.4M ARR, 88% retention), Legacy DSS ($38.5M ARR, 48% GM) and Services ($62.4M, 48% GM) deliver stable cash flows; FY2025 surplus $16.4M funds autonomous R&D.
| Product | 2025 ARR | GM | Notes |
|---|---|---|---|
| Data Integration | $85M | 60% | 72% new deals |
| Healthcare Analytics | $48.3M | 38% | 92% retention |
| Dashboards | $18.4M | - | 62% C-suite share |
| Legacy DSS | $38.5M | 48% | 420 clients |
| Services | $62.4M | 48% | covers 14% opex |
What You're Viewing Is Included
Aily Labs BCG Matrix
The file you're previewing is the exact Aily Labs BCG Matrix report you'll receive after purchase-no watermarks, placeholders, or demo content. Fully formatted and analysis-ready, the document arrives immediately for editing, printing, or presenting to stakeholders. Crafted with market-backed insights and strategic clarity, it requires no revisions and can be integrated straight into your planning, pitch decks, or client deliverables.
